Avalo Therapeutics (AVTX) Receivables - Net (2016 - 2023)
Avalo Therapeutics' (AVTX) quarterly Receivables - Net came in at $38000.0 in Q2 2023, down 95.78% YoY from $900000.0 in Q2 2022, and down 95.25% on a QoQ basis from $800000.0 in Q3 2022.
Avalo Therapeutics (AVTX) Receivables - Net (2016 - 2023) Analysis & Trends
Avalo Therapeutics (AVTX) has 8 years of Receivables - Net data on file, last reported at $38000.0 in Q2 2023.
- Quarterly Receivables - Net fell 95.78% year-over-year to $38000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $38000.0 (down 95.78% YoY) and the FY2021 annual result came in at $1.1 million, down 51.31% from the prior year.
- Receivables - Net fell to $38000.0 in Q2 2023, from $800000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $5.5 million in Q1 2019 to a low of $38000.0 in Q2 2023.
- A 5-year average of $1.9 million and a median of $1.6 million in 2020 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2019 — Receivables - Net jumped 3149.59% — and 2023, when it tumbled 95.78%.
- Tracing AVTX's Receivables - Net over 5 years: stood at $1.0 million in 2019, then soared by 117.34% to $2.2 million in 2020, then tumbled by 51.31% to $1.1 million in 2021, then retreated by 24.53% to $800000.0 in 2022, then slumped by 95.25% to $38000.0 in 2023.
- The last three Receivables - Net figures came in at $38000.0 (Q2 2023), $800000.0 (Q3 2022), and $900000.0 (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 38,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Sep 30, 2022 | 800,000.00 |
| Sep 30, 2022 | 800,000.00 |
| Jun 30, 2022 | 900,000.00 |
| Jun 30, 2022 | 900,000.00 |
| Mar 31, 2022 | 938,000.00 |
| Mar 31, 2022 | 938,000.00 |
| Dec 31, 2021 | 1.06 Mn |
| Dec 31, 2021 | 1.06 Mn |
| Sep 30, 2021 | 1.44 Mn |
| Sep 30, 2021 | 1.44 Mn |
| Jun 30, 2021 | 4.12 Mn |
| Jun 30, 2021 | 4.12 Mn |
| Mar 31, 2021 | 3.13 Mn |
| Mar 31, 2021 | 3.13 Mn |
| Dec 31, 2020 | 2.18 Mn |
| Dec 31, 2020 | 2.18 Mn |
| Sep 30, 2020 | 1.67 Mn |
| Sep 30, 2020 | 1.67 Mn |